In animal studies, navitoclax was found to be a [[senolytic]] agent, inducing [[apoptosis]] in [[cellular senescence|senescent]], but not non-senescent cells.<ref>{{cite journal|last1=Zhu|first1=Y|last2=Tchkonia|first2=T|last3=Fuhrmann-Stroissnigg|first3=H|last4=Dai|first4=HM|last5=Ling|first5=YY|last6=Stout|first6=MB|last7=Pirtskhalava|first7=T|last8=Giorgadze|first8=N|last9=Johnson|first9=KO|last10=Giles|first10=CB|last11=Wren|first11=JD|last12=Niedernhofer|first12=LJ|last13=Robbins|first13=PD|last14=Kirkland|first14=JL|title=Identification of a Novel Senolytic Agent, Navitoclax, Targeting the Bcl-2 Family of Anti-Apoptotic Factors|journal=Aging Cell|date=2015|doi=10.1111/acel.12445|pmid=26711051}}</ref> Oral administration of ABT263 to either sublethally irradiated or normally aged mice reduced senescent cells, including senescent bone marrow hematopoietic stem cells and senescent muscle stem cells. This depletion mitigated total-body irradiation-induced premature aging of the hematopoietic system and rejuvenated the aged hematopoietic stem cells and muscle stem cells in normally aged mice.<ref name="pmid26657143">{{cite journal | vauthors = Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, Krager K, Ponnappan U, Hauer-Jensen M, Meng A, Zhou D | title = Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice | journal = Nature Medicine | volume = 22| issue = | pages = 78â€“83| year = 2015 | pmid = 26657143 | doi = 10.1038/nm.4010 | url = http://dx.doi.org/10.1038/nm.4010 | accessdate = 2015-12-23 | pmc=4762215}}</ref>

 

